Foundation for Innovative New Diagnostics (FIND)

Attempts to tackle antimicrobial resistance (AMR) to preserve the effectiveness of antibiotic drugs and save lives. Works towards enhancing access to AMR testing at primary care level to prevent further development of AMR. In hospitals, the aim is to improve diagnosis for severe bloodstream infections and neonatal sepsis to reduce AMR-related deaths. Additionally, it also supports the development of digital tools for AMR surveillance and antimicrobial stewardship, following the One Health approach.

Our goal is to accelerate the elimination of neglected tropical diseases (NTDs) by implementing tailored testing strategies. NTDs, a diverse group of 20 diseases, disproportionately affect marginalized communities, especially women and children. The organisation’s NTD strategy focuses on improving diagnosis and surveillance for diseases like Buruli ulcer, Chagas disease, sleeping sickness, visceral leishmaniasis, lymphatic filariasis, onchocerciasis, and schistosomiasis. It collaborates with partners to establish a transparent diagnostic pipeline aligned with WHO NTD 2021-2030 roadmap, advocate for critical product and funding support, develop novel rapid diagnostic tests, support local production of diagnostic tests, evaluate new diagnostic tests for certain NTDs, create specimen banks, and strengthen country capacity for testing in endemic areas.

The organisation’s cervical cancer strategy focuses on helping countries achieve the WHO's goal of eliminating cervical cancer as a public health problem. This is done by promoting the rapid adoption of HPV-based cervical screening and implementing women-centered screening models in low- and middle-income countries. The organisation collaborates with partners to support community-led advocacy and education to scale up screening, accelerate the adoption of women-centric technology, and improve access to affordable screening tests. The aim is to increase screening rates and save lives from cervical cancer.

The organisation’s TB strategy aims to reduce the diagnostic gap by developing new tests and improving community-based testing. It also focuses on integrated testing for respiratory symptoms to detect missed TB cases and similar conditions like COVID-19. Collaborates with partners to expand resources for TB diagnostics, evidence dossiers for policy evaluation, new TB tests, and molecular testing uptake.